← All trials
NCT05283109
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2022
- Primary completion
- Apr 30, 2025
- Completion date
- Feb 29, 2028
- First posted
- Mar 16, 2022
- Last posted
- Aug 18, 2022
- Enrollment
- 36
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Duke UniversityLead sponsor
- National Cancer Institute (NCI)Collaborator
- Duke UniversityOverall official - principal investigator
- Duke UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.